5.2 Parkinsons disease Parkinsons disease is the second most common chronic and late-onset neurodegenerative disease after Alzheimers disease, with clinical features including slowness of facial expression, increased muscle tension throughout the body, bradykinesia, progressive resting tremor, and dementia (Nishioka and Hattori, 2020)
In vivo experiments in tail-suspended mouse models confirmed that LASSS treatment significantly reduces HGF nitration and preserves muscle repair signals, offering a promising therapeutic target for sarcopenia, age-related atrophy, and prolonged disuse
This threshold is supported by volunteer studies using semaglutide, where residual solids were detected on ultrasound despite 8 h fasting [7], and by matched-pair data showing a five-fold rise in endoscopic residue among GLP-1RA users 7
Possible side effects Like all medicines, GLP-1 therapies can cause side effects
Patients must learn how to inject themselves safely and properly